QR-Code

In vivo Effects of Romidepsin on T-Cell Activation, Apoptosis and Function in the BCN02 HIV-1 Kick&Kill Clinical Trial

Romidepsin (RMD) is a well-characterized histone deacetylase inhibitor approved for the treatment of cutaneous T-cell lymphoma. in vitro and in vivo studies have demonstrated that it is able to induce HIV-1 gene expression in latently infected CD4+ T cells from HIV-1+ individuals on suppressive anti...

Ausführliche Beschreibung

Gespeichert in:
Hauptverfasser: Miriam Rosás-Umbert, Marta Ruiz-Riol, Marco A. Fernández, Marta Marszalek, Pep Coll, Christian Manzardo, Samandhy Cedeño, José M. Miró, Bonaventura Clotet, Tomáš Hanke, José Moltó, Beatriz Mothe, Christian Brander, the BCN02 study group, Susana Benet, Anuksa Llano, Javier Martinez-Picado, Sara Morón-López, Roger Paredes, Maria C. Puertas, Roser Escrig, Silvia Gel, Miriam López, Cristina Miranda, Jose Muñoz, Nuria Perez-Alvarez, Jordi Puig, Boris Revollo, Jessica Toro, Ana Maria Barriocanal, Magi Farré, Cristina Perez-Reche, Marta Valle, Juan Ambrosioni, Irene Ruiz, Cristina Rovira, Carmen Ligero, Jose M. Miro, Antonio Carrillo, Michael Meulbroek, Ferran Pujol, Jorge Saz, Nicola Borthwick, Alison Crook, Edmund G. Wee
Format: Artigo
Sprache:Inglês
Veröffentlicht: Frontiers Media S.A. 2020-03-01
Schriftenreihe:Frontiers in Immunology
Schlagworte:
romidepsin
HDAC inhibitor
kick&kill strategy
therapeutic vaccine
latency reversing agent (LRA)
Online-Zugang:https://www.frontiersin.org/article/10.3389/fimmu.2020.00418/full
Tags: Tag hinzufügen
Keine Tags, Fügen Sie das erste Tag hinzu!

Ähnliche Einträge